Medincell SA
Research Medincell SA (MEDCL) on Bullrun: market cap EUR 797.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMEDCL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 797.47M
- Financial periodFY2025
- RevenueEUR 25.54M
- Revenue growth178.8%
- Net income-EUR 18.44M
- Free cash flowEUR 17.81M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 797.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 25.54M | -EUR 18.44M | EUR 17.81M | 100.0% | -0.62 | EUR 59.04M | EUR 58.76M | -EUR 16.37M |
| FY2024 | EUR 9.16M | -EUR 25.04M | -EUR 13.11M | 100.0% | -0.86 | EUR 19.46M | EUR 58.96M | -EUR 40.82M |
| FY2023 | EUR 9.94M | -EUR 32.01M | -EUR 22.03M | 100.0% | -1.27 | EUR 6.47M | EUR 54.65M | -EUR 42.29M |
| FY2022 | EUR 4.09M | -EUR 24.81M | -EUR 23.34M | 100.0% | -1 | EUR 24.62M | EUR 47.49M | -EUR 13.37M |
| FY2021 | EUR 8.34M | -EUR 24.81M | -EUR 22.99M | 100.0% | -1 | EUR 24.62M | n/a | -EUR 13.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | EUR 797.47M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Medincell SA
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medincell SA's market cap?
Medincell SA's market capitalization is EUR 797.47M.
What does Medincell SA do?
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation.